Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo, Canadian Biotech Expand Joint Research on Bispecific Antibodies
Daiichi Sankyo announced on May 15 that it will expand its joint research with Canadian biotech Zymeworks in the field of oncology. In addition to a cross-licensing agreement related to bispecific antibodies sealed in 2016, Daiichi Sankyo will acquire the…
To read the full story
Related Article
- Daiichi Sankyo Exercises Option to Commercialize Bispecific Antibodies Based on Joint Research with Zymeworks
May 7, 2019
- Zymeworks Gains US$1 Million from Daiichi Sankyo in Bispecific Antibody Milestone
July 20, 2017
- Daiichi Sankyo, Zymeworks Seal Immuno-Oncology Cross-Licensing Pact
September 30, 2016
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…